ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 15.9% from a year ago
Net receivables stood at $255.43M at the end of Q1 FY2026, up 15.9% from a year earlier and down 9.1% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.
Context
- Net receivables amounted to 18.0% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +15.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 281.08M USD
- Year-over-year change
- +26.8%
- 4-year CAGR
- +21.6%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 281.08M | +26.8% |
| FY2024 | 2024-12-31 | 221.73M | +36.8% |
| FY2023 | 2023-12-31 | 162.08M | -2.0% |
| FY2022 | 2022-12-31 | 165.44M | +28.7% |
| FY2021 | 2021-12-31 | 128.53M | — |
Net Receivables vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +15.9% is the 3rd highest of 10, against a peer median of +2.0%.
- Net receivables amounts to 18.0% of total assets for ANIP, versus a peer median of 14.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹101.84B INR | -15.7% | +6.0% | 17.7% | |
| Jun 2026 | $3.67B USD | +2.0% | -6.9% | 10.5% | |
| Jun 2026 | $3.49B USD | -2.0% | +0.1% | 8.8% | |
| Jun 2026 | $2.26B USD | +2.4% | +9.4% | 9.1% | |
| Jun 2026 | $1.02B USD | +20.2% | +8.2% | 27.0% | |
| Mar 2026 | $255.43M USD | +15.9% | +19.3% | 18.0% | |
| Mar 2026 | $228.76M USD | +0.0% | +4.9% | 13.8% | |
| Mar 2026 | $147.85M USD | +1.7% | +17.4% | 9.0% | |
| Mar 2026 | $101.26M USD | +31.0% | +158.9% | 24.1% | |
| Mar 2026 | $52.22M USD | +10.0% | +34.6% | 23.7% | |
| Dec 2025 | $33.82M USD | — | — | 14.6% | |
| Peer median (excluding ANIP) | — | +2.0% | +8.2% | 14.2% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 100.3M | 48.23M | 221.12M | 144.86M | 285.59M |
| Short-term Investments | 0 | 0 | 0 | 6.31M | 0 |
| Net Receivables | 128.53M | 165.44M | 162.08M | 221.73M | 281.08M |
| Inventory | 81.69M | 105.36M | 111.2M | 136.78M | 143.07M |
| Other Current Assets | 3.67M | 21.41M | 25.42M | 18.01M | 43.38M |
| Total Current Assets | 321.78M | 344.26M | 519.82M | 527.68M | 753.12M |
| Property, Plant & Equipment (Net) | 52.67M | 43.25M | 44.59M | 56.86M | 62.48M |
| Goodwill | 27.89M | 28.22M | 28.22M | 59.99M | 62.48M |
| Intangible Assets | 294.12M | 251.64M | 209.01M | 541.83M | 479.53M |
| Long-term Investments | 5M | 0 | 6.2M | 0 | 0 |
| Tax Assets | 67.94M | 81.36M | 90.71M | 85.11M | 69.07M |
| Other Non-current Assets | 2.21M | 11.36M | 5.87M | 12.22M | 13.71M |
| Total Non-current Assets | 449.82M | 415.83M | 384.61M | 756.01M | 687.26M |
| Total Assets | 771.6M | 760.09M | 904.42M | 1.28B | 1.44B |
| Account Payables | 22.97M | 29.31M | 36.68M | 45.66M | 62.58M |
| Short-term Debt | 850K | 850K | 850K | 9.17M | 17.27M |
| Tax Payables | 3.67M | 0 | 8.16M | 6.75M | 11.03M |
| Deferred Revenue | 87K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 44.27M | 43.71M | 65.73M | 77.03M | 198.26M |
| Total Current Liabilities | 87.54M | 99.44M | 145.48M | 193.68M | 278.11M |
| Long-term Debt | 286.52M | 285.67M | 284.82M | 614.92M | 307.93M |
| Deferred Tax Liabilities | 9.49M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | (9.49M) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 38.8M | 36.44M | 16.53M | 46.57M | 313.61M |
| Total Non-current Liabilities | 325.32M | 322.11M | 301.35M | 661.49M | 621.54M |
| Total Liabilities | 412.86M | 421.55M | 446.82M | 855.17M | 899.65M |
| Common Stock | 1K | 1K | 2K | 2K | 3K |
| Retained Earnings | (47.77M) | (97.29M) | (80.13M) | (100.28M) | (23.1M) |
| Accumulated OCI | (3.06M) | 12.17M | 8.86M | 5.34M | 1.03M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 358.74M | 338.54M | 457.6M | 428.53M | 540.72M |
| Total Debt | 287.37M | 286.52M | 285.67M | 624.09M | 325.2M |
| Net Debt | 187.07M | 238.29M | 64.55M | 479.23M | 39.61M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.